(0.01%) 5 479.25 points
(-0.01%) 38 814 points
(0.06%) 19 934 points
(0.27%) $80.55
(1.18%) $2.82
(0.09%) $2 331.10
(-0.48%) $29.25
(-0.12%) $969.70
(0.03%) $0.932
(-0.11%) $10.64
(0.08%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases...
Stats | |
---|---|
Šios dienos apimtis | 2.76M |
Vidutinė apimtis | 634 418 |
Rinkos kapitalizacija | 135.20M |
EPS | $-0.0582 ( Q3 | 2023-11-13 ) |
Kita pelno data | ( $0 ) 2024-08-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.04 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0960 (14.39%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Singer Michael | Buy | 178 000 | Common Stock |
2024-01-02 | Singer Michael | Buy | 228 000 | Stock Option (Right to Buy) |
2023-12-22 | Singer Michael | Sell | 3 000 | Series A Convertible Preferred Stock |
2024-01-02 | Davis Blaine | Buy | 3 110 000 | Employee Stock Option (right to buy) |
2024-01-02 | Davis Blaine | Buy | 2 424 000 | Common Stock |
INSIDER POWER |
---|
53.21 |
Last 97 transactions |
Buy: 26 530 299 | Sell: 8 848 103 |
Tūris Koreliacija
Selecta Biosciences Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Selecta Biosciences Inc Koreliacija - Valiuta/Žaliavos
Selecta Biosciences Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $-0.00140 |
FY | 2022 |
Pajamos: | $110.78M |
Bruto pelnas: | $38.40M (34.66 %) |
EPS: | $0.240 |
FY | 2021 |
Pajamos: | $85.08M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.220 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Selecta Biosciences Inc
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.